Chief Legal Officer · Acumen Pharmaceuticals, Inc. (ABOS)

Derek Meisner

A named executive officer of Acumen Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,476,637

Salary $455,663Stock awards $163,748Bonus $45,000

FY2022: $1,279,668

3rd of 3 named executive officers at Acumen Pharmaceuticals by FY2023 total.

3 named officers on file for Acumen Pharmaceuticals, FY2023

Derek Meisner’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Acumen Pharmaceuticals’s whole pay program stands against its peers

  • Acumen Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABOS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Derek Meisner’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Derek Meisner compensation by year

Acumen Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Acumen Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$141,705$455,663
Bonus$45,000$45,000
Stock awards$0$163,748
Option awards$1,039,500$559,944
Non-equity incentive$52,925$236,945
Pension and deferred compensation$0$0
All other$538$15,337
Total$1,279,668$1,476,637

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Acumen Pharmaceuticals, Inc. DEF 14A filed April 22, 2024, accession 0001576885-24-000055, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Acumen Pharmaceuticals, Inc. filed document, accession 0001576885-24-000055. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2024.

$1.3M
$1.5M
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU26,800$102,912—
Option154,688—$6.08
Option93,117—$6.11

Per the Outstanding Equity Awards at Fiscal Year-End table in Acumen Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

30 Form 4 lines since the FY2023 proxy (filed April 22, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-06Sale10b5-12,090$3.26173,999
2026-03-06Exercise or conversion10b5-12,090$1.85176,089
2026-03-06Exercise or conversion derivative10b5-12,090$0.0071,048
2026-02-27Exercise or conversion10b5-19,406$1.85183,405
2026-02-27Sale10b5-19,406$3.01173,999
2026-02-27Exercise or conversion derivative10b5-19,406$0.0073,138
2026-01-28Exercise or conversion10b5-12,671$1.85176,670
2026-01-28Exercise or conversion derivative10b5-12,671$0.0082,544

The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Acumen Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Daniel O'ConnellChief Executive Officer$3,930,011
Matthew ZugaChief Financial Officer and Chief Business Officer$1,606,289
Derek Meisner · this pageChief Legal Officer$1,476,637

The full Acumen Pharmaceuticals compensation record

free company brief

This page is one person within Acumen Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Acumen Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Derek Meisner's compensation dossier · One-time report. No refunds.